About Pricing FAQs Providers Trials Blog

Back to your record

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Deep Learning on Amyloid Positons Emission Tomography

NCT07309107·3 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Antoine VERGER, MD,PhD
CONTACT
0383155567 a.verger@chru-nancy.fr
Veronique Roch, MSc
CONTACT
0383154276 v.roch@chru-nancy.fr

Lead

Central Hospital, Nancy, France

Age

18–99

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Patients with objective cognitive impairment,
Referred to our department for a cerebral \[¹⁸F\]flutemetamol positron emission tomography scan between January 1, 2023 and July 1, 2025,

You may not be if

Patient have objected to the use of their data.

The record

StatusRecruiting

PhaseNo phase

Taking part40

StartedMay 2026

UpdatedJun 25, 2026

Conditions

Alzheimer Disease

Where3

CHRU NANCY Brabois, nuclear medicine department
Vandœuvre-lès-Nancy, France
Nancy's hospital
Vandœuvre-lès-Nancy, France
Nuclear medicine department CHRU de NANCY Brabois
Vandœuvre-lès-Nancy, France